Karyopharm Therapeutics Inc (FRA:25K)
€ 0.5734 -0.0194 (-3.27%) Market Cap: 84.88 Mil Enterprise Value: 143.15 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 64/100

Karyopharm Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 17, 2022 / 08:35PM GMT
Release Date Price: €5.35 (-1.71%)
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

Good afternoon, everyone. I'm Brian Abrahams, one of the senior biotech analysts at RBC Capital Markets. Our last session on day 1 of our health care conference is going to be featuring Karyopharm. Really happy to have with us their CEO, Richard Paulson; and their new Chief Medical Officer, Reshma Rangwala. So Richard and Reshma, thanks again for joining us, and it's great to see you guys in person.

Reshma Rangwala
Karyopharm Therapeutics Inc. - Chief Medical Officer

Absolutely.

Richard A. Paulson
Karyopharm Therapeutics Inc. - President, CEO & Director

Thank you for having us. It's wonderful to see people in person again.

Questions & Answers

Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

Indeed. So maybe just to start things off on the commercial side with XPOVIO, you've -- you successfully launched the drug into a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot